category,datetime,headline,id,image,related,source,summary,url
company,1768950434,"Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer",138191068,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRNA,Yahoo,"On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.",https://finnhub.io/api/news?id=7a9032692e3115cacffd37c6f6133c77666214b97c7f1b92b0360d20058bdd23
company,1768950002,Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know,138191635,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRNA,Yahoo,"Moderna (MRNA) closed at $43 in the latest trading session, marking a +2.8% move from the prior day.",https://finnhub.io/api/news?id=40c823f1c4c9f74f3c069929e35bacfe5b464f2f5e1494192a3eed3c5e3fd121
company,1768941060,"Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?",138199138,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRNA,Yahoo,"COVID-19 vaccine stock Moderna just got its biggest lift in recent memory, moving up 17%. Can MRNA stage a broader recovery, down +90% from its all-time high?",https://finnhub.io/api/news?id=58e0c79bdbe42611b1e4e0f15f558036b8c6b96ce43a711c970c51dc031686c1
company,1768910280,"Moderna, Merck Report Positive Results From Cancer-Vaccine Study",138186680,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRNA,Yahoo,"Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.",https://finnhub.io/api/news?id=1513dc35651e967fc1735d59c48d413568b70e6df6c6611ae8118c5380258707
company,1768906800,Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection,138185701,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRNA,Yahoo,"At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA alone ...",https://finnhub.io/api/news?id=bc451509fa838b9994d3707b3cc1d826b4277dcf21798801071dc9498daa3177
company,1768905480,Moderna cancer vaccine holds up; IO Biotech considers a sale,138196066,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MRNA,Yahoo,"Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target and Pfizer tapped Novavax for vaccine assistance.",https://finnhub.io/api/news?id=a56a24a15fde389023f49f92ef165d6333be138cc6b3f040b9aa90efd9fae863
